Adenosine deaminase deficiency

From Wikipedia, the free encyclopedia

ICD9 = | ICDO = | OMIM = 102700 | MedlinePlus = | eMedicineSubj = | eMedicineTopic = | MeshID = |Adenosine deaminase deficiency, or ADA deficiency, is an inherited immunodeficiency syndrome accounting for about 25% of all cases of severe combined immunodeficiency (SCID).This disease is due to a lack of the enzyme adenosine deaminase coded for by a gene on chromosome 20. There is an accumulation of dATP, which causes an increase in S-adenosylhomocysteine; both substances are toxic to immature lymphoid cells, so fail to reach maturity. As a result, the immune system of the afflicted person is severely compromised or completely lacking.The enzyme adenosine deaminase is important for purine metabolism.

Treatment

Treatments include:
  • bone marrow transplant
  • gene therapy (efforts halted due to increased incidence of leukemia)
  • ADA enzyme in PEG vehicle
  • Stem Cell Therapy (still in the experimental stage)
    • On September 14, 1990, the first gene therapy to combat this disease was performed by Dr. W. French Anderson on a four year old girl, Ashanti DeSilva, at the National Institute of Health, Bethesda, Maryland, U.S.A.The therapy performed was the first successful case of gene therapy.

    External link

  • Gene Therapy: A Brief History: [http://www.family.org/cforum/fosi/bioethics/genetics/a0032608.cfm]
  • Gene Therapy Net


    • Next Page


    This article is based on an article from Wikipedia, the free encyclopedia and is available under the terms of GNU Free Documentation License.
    In the Wikipedia there is a list with all authors of this article available.